GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rennova Health RNVA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$18.7m

FY2015FY2024

Net income

−$7.7m

FY2015FY2024

Free cash flow

$3.0m

FY2015FY2024

Shareholders' equity

−$36.8m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue$18.7m$18.7m$13.0m$3.2m$7.2m$16.0m$14.5m$3.1m$3.3m$498,000
Research and development————————$2.1m$2.2m
Operating income$1.4m$1.4m−$1.4m−$12.5m−$17.2m−$15.7m−$13.1m−$16.1m−$21.5m−$5.4m
Net income−$7.7m−$7.7m−$3.3m$5.6m−$18.3m−$48.0m−$14.0m−$55.2m−$32.6m−$5.2m
Diluted earnings per share-0.00-0.00-0.00127.68-0.46-49.78-0.11-2.79-11.65-0.04

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$20.3m$20.3m$20.6m$19.6m$12.3m$14.7m$14.2m$6.3m$6.5m$9.3m
Cash and short-term investments$49,015—$499,470$724,524$25,353$16,933$6,870−$2.1m$77,979—
Total liabilities$57.1m$57.1m$49.7m$46.9m$61.3m$83.6m$53.4m$41.1m$21.4m$1.4m
Debt$11.8m$8.2m$15.1m$16.1m$22.0m$50.2m$20.8m$15.5m$12.9m$533,000
Shareholders' equity−$36.8m−$36.8m−$29.1m−$27.3m−$49.0m−$68.9m−$39.2m−$34.8m−$14.9m$7.9m
Shares outstanding32,826m40,551m29,084m0m40m1m129m20m3m119m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations$3.4m$3.4m−$218,348−$8.9m−$16.9m−$13.5m−$7.7m−$17.7m−$19.9m−$3.6m
Capital spending−$350,934−$350,934−$35,230−$35,230−$370,891−$125−$213,105−$1.4m−$18,060−$17,000
Free cash flow$3.0m$3.0m−$253,578−$8.9m−$17.3m−$13.5m−$7.9m−$19.1m−$19.9m−$3.6m
Dividends paid———−$9.0m———−$24.5m−$16.3m−$441,311

Latest quarters

By quarter end

Dec 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022
Revenue$3.8m$3.8m$3.5m$6.4m$4.9m$5.5m$2.8m$3.6m
Operating income−$882,329−$882,331−$600,973$2.1m$752,045$1.4m−$924,812$37,180
Net income−$9.3m−$9.3m−$548,229$1.3m$805,560$331.7m−$1.3m−$503,785
Diluted earnings per share-0.00-0.00-0.000.000.000.01-0.00-0.00
Cash from operations———$2.0m$1.0m$1.0m——
Total assets$20.3m$20.3m$19.8m$21.6m$20.6m$20.6m$20.3m$19.2m
Cash and short-term investments$49,015—$123,898$725,517$251,221—$10,958$126,874
Debt$3.4m$8.2m$12.0m$12.2m$13.5m—$14.8m$14.7m
Shareholders' equity−$36.8m−$36.8m−$27.6m−$27.0m−$28.3m−$29.1m−$29.9m−$28.6m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue79.6%3.1%43.7%
Net income—-30.6%4.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin7.3%-20.9%-57.4%-106.8%
Net margin-41.4%-24.5%-103.5%-194.0%

Valuation history

At each fiscal year end

FY2024FY2023FY2020FY2017FY2015
Price to earnings-0.4-0.1-0.1—-0.2
Price to sales0.20.00.20.02.2

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%700%6300%-95%-100%315037%619%-100%29%-86%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10000-to-1 reverse split · 16 Mar 2022
  • 1000-to-1 reverse split · 19 Jul 2021
  • 10000-to-1 reverse split · 3 Aug 2020
  • 500-to-1 reverse split · 13 Nov 2018
  • 15-to-1 reverse split · 6 Oct 2017
  • 30-to-1 reverse split · 23 Feb 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.